Indeed, inhibition of either GFPT2 (glutamine-fructose-6-phosphate transaminase 2), a central enzyme of the hexosamine pathway, or the acetyl-coA carboxylase (ACAC, key for fatty acid synthesis), blocks NSCLC tumor growth [126,127]. The gene discussed is GFPT2; the disease is neoplasm.